Presbyopia Market Forecast to Reach Approximately USD 18 Billion by 2036 as Pharmacological Innovation Accelerates

ResearchAndMarkets added a report, “Presbyopia - Market Insight, Epidemiology, and Market Forecast - 2036,” covering the presbyopia market, treatment landscape, pipeline activity, and commercial outlook across the US, key EU countries, the UK, and Japan. The news is informational with no stated company financials, regulatory outcomes, or treatment results, suggesting minimal near-term market impact.

Analysis

This is a sentiment signal for ophthalmology, not a fundamental catalyst. The only near-term beneficiary is the sub-sector getting incremental investor attention: presbyopia-focused drug developers and eye-care commercial platforms that can convert a niche indication into high-frequency repeat prescribing. That tends to favor the names with existing eye-doctor distribution and marketing muscle, while pure pipeline stories remain valuation-sensitive to even small misses on efficacy, duration, or tolerability.

The second-order effect is competitive, not absolute: if one product wins on convenience or side-effect profile, it can displace a broader bucket of dry-eye and refractive-correction spend rather than expand total addressable demand proportionally. The market often assumes a large addressable population automatically translates into revenue, but in eye care the real bottleneck is reimbursement friction and adoption speed. That means the first 1-3 months after any pipeline/data catalyst can be noisy, while the 6-18 month outcome depends on repeat usage rates and physician habit formation more than prevalence charts.

Contrarian view: the market may be overestimating monetization and underestimating churn. Presbyopia is chronic, but chronic does not equal sticky if the product is inconvenient, causes headaches/near-vision tradeoffs, or is priced like a premium eye drop. I would treat this as a watch item for the ophthalmology basket rather than a standalone trade until there is evidence of payer coverage or a durable commercial launch curve.

Key Decisions for Investors

• No immediate directional trade on the report alone; treat as a sector watchlist item until a clinical or commercialization catalyst appears.
• Add ABBV, BLCO, and LENZ to a presbyopia-focused monitoring basket; only consider longs if upcoming data show differentiated efficacy/duration with manageable tolerability and clear prescribing convenience.
• If the market starts capitalizing presbyopia TAM aggressively, consider a relative-value short against the broader ophthalmology basket or a generic healthcare proxy, because the first move is likely to outpace near-term monetization.
• Set an alert for any reimbursement or launch-readthrough within 1-3 months; a positive coverage decision would be the first real catalyst for multiple expansion, while weak uptake would likely compress early optimism.